Search Browse Earnings

4D Molecular Therapeutics, Inc.

Nasdaq:FDMT

Biological Products, (No Diagnostic Substances)·EMERYVILLE, CA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

4D Molecular Therapeutics, Inc. — SlamSEC

Revenue

$20.7M

+562.3% YoY

FY 2024

Adj. EBITDA

-$108.7M

-524.4% margin

FY 2024

Net Income

-$100.8M

-486.6% margin

FY 2024

EPS (Diluted)

-$2.58

FY 2024

Stock Price

$8.47

-1.9%

2026-03-06

52W Range

$2.23 – $12.34

P/E Ratio

-3.3x

Market Cap

$421.9M

Cash

$249.1M

FY 2024

Total Debt

—

Net Cash

$249.1M

FY 2024

Enterprise Value

$172.8M

Debt / EBITDA

2.3x

FY 2024

EV / EBITDA

-1.6x

Employees

—